For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250218:nRSR4219Xa&default-theme=true
RNS Number : 4219X Eco Animal Health Group PLC 18 February 2025
18 February 2025
ECO Animal Health Group plc
("ECO" or the "Company")
BLOCK LISTING RETURN
Name of applicant: ECO Animal Health Group plc
Name of scheme: Executive Share Option Scheme and Unapproved Share Option Scheme
Number and class of securities originally listed and the date of admission: 1,500,000 ordinary shares of 5 pence each on 20 July 2017
Period of return: From: 9 August 2024 To: 9 February 2025
Balance of unallotted securities under scheme(s) from previous return: 375,505
Plus: The amount by which the block scheme(s) has been increased since the 0
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period: 0
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 375,505
-Ends-
For further information please contact:
ECO Animal Health Group plc 020 8447 8899
David Hallas (CEO)
Christopher Wilks (CFO)
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Phil Davies
Sam Butcher
Investec (Joint Broker) 020 7597 5970
Gary Clarence
Lydia Zychowska
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
ICR Healthcare (Financial PR) 020 3709 5700
Mary-Jane Elliott ecoanimalhealth@consilium-comms.com
Jessica Hodgson
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BLRGPUUCPUPAGMM